Myriad Genetics, Inc. is a company within the Healthcare category. Myriad Genetics, Inc. is a leading molecular diagnostics company that develops and markets genetic tests to assess the risk of developing disease, guide treatment decisions, and assess disease progression. Known for pioneering the first commercial tests for hereditary breast and ovarian cancer, the company now provides services across oncology, women's health, and mental health.
Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, UT.
Myriad Genetics, Inc. is rated Leader on the Optimly Brand Authority Index, a measure of how well AI models can accurately describe the brand. The exact score is locked for unclaimed profiles.
AI narrative accuracy for Myriad Genetics, Inc. is Moderate. Significant factual deltas detected. Inconsistent representation across models.
AI models classify Myriad Genetics, Inc. as a Challenger. AI names competitors first.
Myriad Genetics, Inc. appeared in 7 of 8 sampled buyer-intent queries (88%). The brand dominates direct queries but loses share in 'symptom-to-solution' queries where newer, consumer-focused genetic brands (like 23andMe or specific clinical niche startups) are more favored by recent AI training data.
The brand is accurately identified as an industry incumbent in genetic testing. While its historical patent controversy is a major narrative pillar, recent advancements in pharmacogenomics and consumer-facing tests are increasingly recognized. Key gap: AI may still over-emphasize the 2013 Supreme Court patent case (AMP v. Myriad Genetics) as the defining company trait, potentially overshadowing its current portfolio of mental health and prenatal products.
Of 5 key facts verified about Myriad Genetics, Inc., 3 are well-documented (likely accurate across AI models), 2 have limited sourcing, and 0 are retrieval-dependent and may be inaccurate without live search.
Current revenue mix between hereditary cancer vs. mental health (GeneSight) is often misrepresented or outdated in AI summaries.
Buyers turn to Myriad Genetics, Inc. for Traditional Diagnostic Observation: Clinicians using traditional family history and basic pathology without genetic testing., Status Quo Screening: Foregoing genetic testing due to cost or lack of awareness, relying on standard screening., among 2 documented problem areas.
Buyers evaluating Myriad Genetics, Inc. typically ask AI models about "best hereditary cancer genetic testing companies", "pharmacogenomic testing for depression treatment", "BRCA1 BRCA2 testing providers", and 3 similar queries.
Myriad Genetics, Inc.'s main competitors are Foundation Medicine, Invitae, Natera. According to AI models, these are the brands most frequently named alongside Myriad Genetics, Inc. in buyer-intent queries.
Myriad Genetics, Inc.'s core products are Molecular diagnostic tests (MyRisk, GeneSight, Prequel, Prolaris, SneakPeek).
Myriad Genetics, Inc. uses Insurance-based, Medicare/Medicaid, and patient-pay programs..
Myriad Genetics, Inc. serves Oncologists, OB/GYNs, Primary Care Physicians, Psychiatrists, and health systems..
Myriad Genetics, Inc. Unequaled clinical dataset and history in hereditary gene discovery, allowing for more accurate variant classification than newer entrants.
Brand Authority Index (BAI) tier: Leader (exact score locked for unclaimed brands)
Archetype: Challenger
https://optimly.ai/brand/myriad-genetics
Last analyzed: April 10, 2026
Founded: 1991
Headquarters: Salt Lake City, Utah, USA